Medicus Pharma (MDCX) Long-Term Debt Issuances (2024 - 2025)
Medicus Pharma (MDCX) reported Long-Term Debt Issuances of $11.9 million for Q4 2025, up 329.41% on a YoY basis from $2.8 million in Q4 2024, and up 363.7% quarter-over-quarter from -$4.5 million in Q3 2025.
Medicus Pharma (MDCX) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Long-Term Debt Issuances for 2 years, with the latest figure at $11.9 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Debt Issuances rose 329.41% year-over-year to $11.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (changed N/A YoY), and the FY2025 full-year result was $11.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $11.9 million, up from -$4.5 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $11.9 million in Q4 2025, with the low at -$5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Medicus Pharma | 7.87 Mn | 7.98 Mn | - | 11.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.87 Mn |
| Dec 31, 2025 | 11.87 Mn |
| Sep 30, 2025 | -4.50 Mn |
| Sep 30, 2025 | -4.50 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.17 Mn |